In CRC patients, the anti-tumor immune responses of Treg are reported to be COX-2/PGE2/cAMP dependent and can be reversed by COX-2 inhibitor, PKA inhibitor, or Treg depletion (6). This evidence concerns the gene PTGS2 and neoplasm.